FN2 Earnings Intelligence
Regeneron Pharmaceuticals, Inc. earnings overview
Latest Regeneron Pharmaceuticals, Inc. (REGN) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Regeneron Pharmaceuticals, Inc.
The supplied analysis supports a constructive but conditional view: Regeneron’s established products showed broad growth and management described a diversified pipeline, but the next phase depends on regulatory execution, clinical development and competition.
Regeneron Pharmaceuticals, Inc.
Regeneron opened fiscal 2026 with a convincing top- and bottom-line beat: revenue up 19% year-over-year to $3.6 billion and non-GAAP EPS rising 15%, driven by accelerating DUPIXENT sales, EYLEA HD growing 52%, and steady Libtayo uptake. The pipeline delivered tangible milestones this quarter, including FDA approval of Otarmeni (a gene therapy for genetic hearing loss, offered free in the U.S.), positive Phase III data for cemdisiran in generalized myasthenia gravis, and advancement of the obesity candidate olatorepatide toward global Phase III. Management maintained the overall revenue and expense outlook while authorizing $3 billion in share repurchases and entering a Most-Favored-Nation pricing agreement with the U.S. government. Despite the operational strength, the stock fell roughly 6% on the report with continued downside drift, as investors appeared to focus on near-term…
Regeneron Pharmaceuticals, Inc.
The supplied analysis supports a constructive but conditional view: established products and a broad late-stage pipeline provide growth support, while regulatory timing, competition, pricing and execution determine whether that trajectory persists.
Regeneron Pharmaceuticals, Inc.
The supplied analysis supports a constructive but qualified view: commercial momentum from Dupixent and EYLEA HD, plus pipeline progress, supports the growth case, while EYLEA pricing pressure, regulatory delays and execution requirements are material counterweights.
Regeneron Pharmaceuticals, Inc.
Regeneron's Q2 2025 showed strong commercial momentum from Dupixent, Libtayo and EYLEA HD, alongside pipeline progress led by Lynozyfic. The case is tempered by lower 2025 guidance, Catalent-related regulatory delays, and competitive and pricing pressure around EYLEA.
Regeneron Pharmaceuticals, Inc.
The supplied analysis supports a constructive but conditional view: Dupixent and EYLEA HD growth, pipeline progress and manufacturing expansion provide growth support, while retinal-market pressure, regulatory execution and rising investment remain material offsets.
Regeneron Pharmaceuticals, Inc.
The supplied analysis supports a constructive but conditional view: product expansion and a broad pipeline can support continued growth, but the thesis depends on offsetting EYLEA competition, executing regulatory milestones and converting clinical programs into approved products.
Get the REGN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.